The immunomodulatory effects of HDAC inhibitors suppressing immune evasion by BRAF-mutant tumors appear to be especially promising, given a growing number of immune therapeutics such as checkpoint inhibitors that have been approved for cancer therapy over the last few years. The gene discussed is HDAC9; the disease is cancer.